Synapse - Sergio Giralt

Results (1053)

Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma

Research Letter

Lin, R. J.; Lobaugh, S. M.; Pennisi, M.; Chan, H. T.; Batlevi, Y.; Ruiz, J. D.; Elko, T. A.; Maloy, M. A.; Batlevi, C. L.; Dahi, P. B.; more...
Haematologica (2021)

Fulltext@MSK | Save

International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

Review

Costa, L. J.; Derman, B. A.; Bal, S.; Sidana, S.; Chhabra, S.; Silbermann, R.; Ye, J. C.; Cook, G.; Cornell, R. F.; Holstein, S. A.; more...
Leukemia (2021)

Fulltext@MSK | Save

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: Results from a multicenter, randomized, phase 2/3 study

Journal Article

Montesinos, P.; Roboz, G. J.; Bulabois, C. E.; Subklewe, M.; Platzbecker, U.; Ofran, Y.; Papayannidis, C.; Wierzbowska, A.; Shin, H. J.; Doronin, V.; more...
Leukemia (2021)

Fulltext@MSK | Save

Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation

Research Letter

Lin, R. J.; Baser, R. E.; Elko, T. A.; Korc-Grodzicki, B.; Shahrokni, A.; Maloy, M. A.; Young, J. W.; Tamari, R.; Shah, G. L.; Shaffer, B. C.; more...
Bone Marrow Transplantation (2021)

Fulltext@MSK | Save

VRd versus KRd safety profiles in newly diagnosed multiple myeloma patients using real-world evidence data from a single institution: VRd has high rates of chronic neuropathy, and KRd has low rates of cardiopulmonary or renal toxicities when using optimized IV fluid management coupled with baseline cardiac workup

Meeting Abstract

Tan, C.; Diamond, B.; Hultcrantz, M.; Korde, N.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Patel, D.; more...
Blood (2020)

Fulltext@MSK | Save

Clinical outcomes of acute myeloid leukemia patients bridged to allogeneic stem cell transplant by venetoclax combination therapy

Meeting Abstract

Stahl, M.; Menghrajani, K.; Derkach, A.; DeWolf, S.; Ruiz, J. D.; Ponce, D. M.; Shaffer, B. C.; Tamari, R.; Young, J. W.; Barker, J.; more...
Blood (2020)

Fulltext@MSK | Save

Maintenance use is more important than the choice of bortezomib-based triplet induction in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation

Meeting Abstract

Sidana, S.; Kumar, S. K.; Fraser, R.; Estrada-Merly, N.; Norkin, M.; Giralt, S.; Qazilbash, M. H.; Shah, N.; D'Souza, A.
Blood (2020)

Fulltext@MSK | Save

Molecular predictors and effectiveness of measurable residual disease (MRD) eradication with chemotherapy and allogeneic stem cell transplantation for acute myeloid leukemia

Meeting Abstract

Stahl, M.; Derkach, A.; Famulare, C.; Cho, C.; Devlin, S.; Farnoud, N.; Menghrajani, K.; Patel, M. A.; Cai, S. F.; Geyer, M. B.; more...
Blood (2020)

Fulltext@MSK | Save

Results of a phase 1 open label dose escalation trial of AB-205 (allogeneic engineered endothelial cell therapy) in adults with lymphoma undergoing high-dose therapy and autologous hematopoietic cell transplantation (HDT-AHCT)